Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
martedì, ottobre 27
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Revolution Medicines Inc
RVMD
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$181.40
-2.50
-1.36%
Ult. Agg.: Oct 26, 5:36 PM
Get Report
Panoramica
Notizie
Previsioni utili
Eventi
Obiettivi di prezzo
Dati finanziari
Sentiment
Azionariato
Confronta
Opzioni
Rapporto azionario
Utili:
I risultati di Q3 2026 tra 8 giorni da adesso in mer nov 4th, dopo la chiusura del mercato
Revolution Medicines Financials
Revolution Medicines (RVMD) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Revolution Medicines Q2 EPS $(3.06) Misses $(1.98) Estimate
Revolution Medicines (NASDAQ:RVMD) reported quarterly losses of $(3.06) per share which missed the analyst consensus estimate of $(1.98) by 54.55 percent. This is a 133.59 percent decrease over losses of $(1.31) per
Benzinga Newsdesk
Earnings Scheduled For May 6, 2026
Benzinga Insights
PRO
Revolution Medicines Sees FY26 GAAP Operating Expenses $1.7B-$1.8B
Benzinga Newsdesk
PRO
Revolution Medicines Q1 EPS $(2.29) Misses $(1.82) Estimate
Revolution Medicines (NASDAQ:RVMD) reported quarterly losses of $(2.29) per share which missed the analyst consensus estimate of $(1.82) by 25.82 percent. This is a 102.65 percent decrease over losses of $(1.13) per
Benzinga Newsdesk
Revolution Medicines: Q4 Earnings Insights
Benzinga Insights
PRO
Revolution Medicines Q4 EPS $(1.86) Misses $(1.58) Estimate. Cash And Equivalents $2.03B
Revolution Medicines (NASDAQ:RVMD) reported quarterly losses of $(1.86) per share which missed the analyst consensus estimate of $(1.58) by 17.87 percent. This is a 66.07 percent decrease over losses of $(1.12) per share
Benzinga Newsdesk
